Targeting Breast Cancers Featuring Activating Mutations in PIK3CA by Generating a Lethal Dose of PIP3
Abstract
Our research described here is relevant to the pathogenesis and a potential novel therapy for breast cancers. The PIK3CA is the most commonly mutated oncogene in breast cancer and loss of the tumor suppressor PTEN occurs frequently in patients suffering from this disease. The most significant accomplishment during the first year of funding is the generation of the oncogenic PIK3CA transgenic animal model which will allow us to determine the oncogenic role of PIK3CA in tumor initiation progression maintenance and metastasis etc. It should also significantly facilitate preclinical testing for the development of PI3K inhibitors for targeted therapy. Our final goal of simultaneous inactivation of PTEN and activation of PIK3CA will not only provide a new perspective on the relationship of the two key oncogene and tumor suppressor PIK3CA and PTEN and the signaling pathway under their control in cell regulation and oncogenic transformation but also a potential novel therapy to all patients plagued with the common tumorigenic mutations.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2007
- Accession Number
- ADA468513
Entities
People
- Jean J. Zhao
Organizations
- Dana–Farber Cancer Institute